<DOC>
	<DOCNO>NCT01558427</DOCNO>
	<brief_summary>Prostate cancer patient diagnose biochemical recurrence limit metastasis conventionally treat androgen deprivation therapy . However , patient limit metastatic load , time progression might . Subsequently , active surveillance patient progression might defer start androgen deprivation therapy ( ADT ) several month year . As alternative , salvage treatment limit number metastasis either surgery radiotherapy might postpone start ADT even longer . The current trial hypothesizes ADT might defer long follow salvage treatment compare active surveillance .</brief_summary>
	<brief_title>Non-systemic Treatment Patients With Low-volume Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven diagnosis prostate cancer ( PCa ) Biochemical relapse PCa follow radical local prostate treatment N1 M1a/b disease imaging , combine maximum 3 synchronous lesion . World Health Organization ( WHO ) performance state 01 Exclusion local relapse Age &gt; =18 year old Signed informed consent Serum testosterone level &lt; 50ng/ml Symptomatic metastasis PSA rise active treatment luteinizing hormonereleasing hormone ( LHRH ) agonist , LHRHantagonist , antiandrogen , maximal androgen blockade , oestrogen Previous treatment cytotoxic agent PCa Treatment past month product know influence Prostate Specific Antigen ( PSA ) level ( e.g . fluconazole , finasteride , corticosteroid , â€¦ ) Disorder preclude understanding trial information inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>